Medications used in the treatment of hypoglycemia due to congenital hyperinsulinism of infancy (HI).
Congenital hyperinsulinism of infancy is the commonest cause of persistent and recurrent hypoglycaemia in the neonatal and infancy period. It is a heterogeneous disorder with respect to clinical presentation, histology, molecular biology and genetics. The biochemical profile is one of hypoketotic, hypofattyacidemic hypoglycemia. To prevent permanent brain damage from hypoglycemia, the treatment of infants with congenital hyperinsulinism must be prompt and aggressive. The drugs used in the medical therapy for congenital hyperinsulinism are diazoxide, octreotide, glucagon and nifedipine.
Hussain
Khalid
K
The London Centre for Paediatric Endocrinology and Metabolism, Great Ormond Street Hospital for Children NHS Trust WC1N 3JH and the Institute of Child Health, University College London, WC1N 1EH United Kingdom. K.Hussain@ich.ucl.ac.uk
Aynsley-Green
Albert
A
Stanley
Charles A
CA
D044903:Congenital Hyperinsulinism / Q000188:drug therapy*; D003981:Diazoxide / Q000627:therapeutic use; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005934:Glucagon / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000151:congenital / Q000188:drug therapy*; D007223:Infant; D009543:Nifedipine / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D005765:Gastrointestinal Agents; D014665:Vasodilator Agents; D005934:Glucagon; D009543:Nifedipine; D003981:Diazoxide; D015282:Octreotide